Topic : Clinical trials / Medical discoveries
- The biotechnology company of the ASISA group has developed a non-invasive tool offering an accuracy of 92% in the diagnosis of breast diseases.
MADRID, November 10, 2022 /PRNewswire/ –Transmural Biotech, the biotechnology company of the ASISA Group, has completed the process established by European regulations for the commercialization of quantusMM, a non-invasive test based on artificial intelligence (AI) which can diagnose diseases breast, including breast cancer, with an accuracy of 92%, from images obtained by means of breast scans.
Obtaining the CE mark is a key step in the development of this technology, as it is also valid for most countries in Asia and Latin America. In the case of Brazil, Transmural has already completed the procedures of the Agncia Nacional de Vigilncia Sanitria (Anvisa) and is awaiting final validation to sell the test on the Brazilian market.
quantusMM is a fast, easy and non-invasive test for the early detection of breast disease, developed from the AI analysis of tens of thousands of anonymous tests. To do this, quantusMM, which is compatible with most modern mammography machines, uploads breast scan images in two perspectives (crniocaudal (CC) and midlateral oblique (MLO)) to a digital platform for automatic analysis. From these breast scans, the algorithm can detect the presence of nodules and malignant micro-calcifications in less than two minutes, helping to identify the risk of breast cancer.
The technology of this tool is based on the quantitative analysis of the texture of the breast image; quantusMM classifies the images and categorizes them on the basis of the BI-RADS system (Breast Imaging-Reporting and Data System), which determines the probability of malignancy of scanned breasts, distinguishing itself from standard categories by the fact that it is based on sensitivity rather than positive predictive values.
quantusMM is designed as a tool to help clinical professionals, in particular for the mass screening of patients with risk factors, for the early detection of breast cancer and the prioritization of waiting lists.
Other tests developed by Transmural Biotech
In addition to quantusMM, Transmural Biotech has developed four other non-invasive, AI-based tests that notably improve the ability to predict a number of diseases: quantusFLM, which predicts fetal lung capacity, allowing specialists establish risks and better prepare for the optimal time and place of birth for each patient; quantusPrematurity, which uses ultrasound of the cervix to predict the risk of premature birth; quantusGL, which determines the level of risk of blindness due to glaucoma; and quantusSkin, which detects malignant skin lesions from dermatoscopy images. These tests are used in more than 320 hospitals or specialized centers around the world.
The quantusSkin test has been included in the Breakthrough Devices program of the US Federal Food and Drug Administration (FDA). This program aims to identify and make available to patients and healthcare professionals all devices likely to provide effective diagnosis or treatment of potentially fatal diseases. The FDA will complete the process in the coming months, granting the tool a marketing license for the United States.
These press releases may also interest you
Press release sent on November 10, 2022 09:31 and distributed by: